Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer

Tomasz (Tom) Beer, Mark Garzotto, W. D. Henner, K. M. Eilers, E. M. Wersinger

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1 (22% of the 37 patients who were initially treated with this regimen). Chemotherapy was suspended until a rise in PSA ≥50% and 1 ng ml-1. The median duration of the first treatment holiday was 20 weeks (13-74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second chemotherapy holiday, and the median duration was 21 weeks (17-28 weeks). Two patients elected to take a third chemotherapy holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95% CI 23.6-29.4 months), and the median survival is 41 months (95% CI 33.7-48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent chemotherapy for AIPC is feasible and deserves further study.

Original languageEnglish (US)
Pages (from-to)1425-1427
Number of pages3
JournalBritish Journal of Cancer
Volume91
Issue number8
DOIs
StatePublished - Oct 18 2004

Fingerprint

Androgens
Prostatic Neoplasms
docetaxel
Drug Therapy
Holidays
Retreatment
Prostate-Specific Antigen
Survival
Calcitriol
Treatment Failure
Therapeutics
Quality of Life
Serum

Keywords

  • Calcitriol
  • Chemotherapy
  • Docetaxel
  • Prostate cancer
  • Vitamin D

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. / Beer, Tomasz (Tom); Garzotto, Mark; Henner, W. D.; Eilers, K. M.; Wersinger, E. M.

In: British Journal of Cancer, Vol. 91, No. 8, 18.10.2004, p. 1425-1427.

Research output: Contribution to journalArticle

@article{8a49346e51104f2b87d7e802a80dc972,
title = "Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer",
abstract = "Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1 (22{\%} of the 37 patients who were initially treated with this regimen). Chemotherapy was suspended until a rise in PSA ≥50{\%} and 1 ng ml-1. The median duration of the first treatment holiday was 20 weeks (13-74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second chemotherapy holiday, and the median duration was 21 weeks (17-28 weeks). Two patients elected to take a third chemotherapy holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95{\%} CI 23.6-29.4 months), and the median survival is 41 months (95{\%} CI 33.7-48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent chemotherapy for AIPC is feasible and deserves further study.",
keywords = "Calcitriol, Chemotherapy, Docetaxel, Prostate cancer, Vitamin D",
author = "Beer, {Tomasz (Tom)} and Mark Garzotto and Henner, {W. D.} and Eilers, {K. M.} and Wersinger, {E. M.}",
year = "2004",
month = "10",
day = "18",
doi = "10.1038/sj.bjc.6602198",
language = "English (US)",
volume = "91",
pages = "1425--1427",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer

AU - Beer, Tomasz (Tom)

AU - Garzotto, Mark

AU - Henner, W. D.

AU - Eilers, K. M.

AU - Wersinger, E. M.

PY - 2004/10/18

Y1 - 2004/10/18

N2 - Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1 (22% of the 37 patients who were initially treated with this regimen). Chemotherapy was suspended until a rise in PSA ≥50% and 1 ng ml-1. The median duration of the first treatment holiday was 20 weeks (13-74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second chemotherapy holiday, and the median duration was 21 weeks (17-28 weeks). Two patients elected to take a third chemotherapy holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95% CI 23.6-29.4 months), and the median survival is 41 months (95% CI 33.7-48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent chemotherapy for AIPC is feasible and deserves further study.

AB - Recently, completed phase III studies demonstrated a survival benefit for a fixed number of cycles of docetaxel-containing chemotherapy treatment of androgen-independent prostate cancer (AIPC). Management of patients who respond well to initial chemotherapy for AIPC remains ill-defined. We previously reported that in a select group of such patients, retreatment with the same regimen was feasible and was associated with quality of life gains. Here, we report that multiple cycles of such intermittent chemotherapy are feasible. We prospectively tested intermittent chemotherapy in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) -1 (22% of the 37 patients who were initially treated with this regimen). Chemotherapy was suspended until a rise in PSA ≥50% and 1 ng ml-1. The median duration of the first treatment holiday was 20 weeks (13-74 weeks) and all patients retained sensitivity to retreatment. Four patients were eligible for a second chemotherapy holiday, and the median duration was 21 weeks (17-28 weeks). Two patients elected to take a third chemotherapy holiday, which lasted 10 and 28 weeks. The median time to treatment failure was 26.5 months (95% CI 23.6-29.4 months), and the median survival is 41 months (95% CI 33.7-48.3 months). Multiple cycles of intermittent chemotherapy interrupted by clinically meaningful treatment holidays are feasible in a subset of AIPC patients treated with this docetaxel-containing regimen. Intermittent chemotherapy for AIPC is feasible and deserves further study.

KW - Calcitriol

KW - Chemotherapy

KW - Docetaxel

KW - Prostate cancer

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=7944219813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944219813&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6602198

DO - 10.1038/sj.bjc.6602198

M3 - Article

VL - 91

SP - 1425

EP - 1427

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -